Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Spectranetics Corp announces FDA clearance of peripheral laser atherectomy devices for In-Stent Restenosis


Wednesday, 23 Jul 2014 04:27pm EDT 

Spectranetics Corp:Receives U.S. Food and Drug Administration (FDA) 510(k) clearance of their peripheral atherectomy products, Turbo-Tandem and Turbo Elite, for treatment of in-stent restenosis (ISR).Clearance prompts a new standard of care in ISR treatment with improved clinical outcomes. 

Company Quote

34.74
0.24 +0.70%
26 Dec 2014